Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of FOLFOX + Erbitux as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type

Trial Profile

Phase II Study of FOLFOX + Erbitux as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms JACCRO CC-05
  • Most Recent Events

    • 19 Jan 2019 Results assessing for carcinoembryonic antigen at baseline and 4 weeks, and with observed survival time from 2 phase II trials (UMIN000004197 and UMIN000007022) presented at the 2019 Gastrointestinal Cancers Symposium.
    • 24 Oct 2017 Results (n=92) of subanalysis of JACCRO CC-05 and JACCRO CC-06 assessing efficacy published in the Targeted Oncology.
    • 21 Jan 2017 Results of a sub analysis of JACCRO CC-05 and JACCRO CC-06 trials presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top